

ICD-O Update
Effective January 1, 2021

Table 7: Combined 2021 ICD-O-3.2 update (alpha)

Status abbreviations used in the update table

Status	Definition
BC	Behavior code change (change in reportability)
CC	Per ICD-O-3.2, several ICD-O codes have been deleted and the histologies moved to other codes.
NC/T	New ICD-O code and term
PT	Preferred term
RT	Related term
Syn	Synonym

Histology terms are per WHO. Preferred terms are indicated in **BOLD** font.

Applicable C codes will be noted next to the term in **BOLD** font.

Coding instructions, if applicable, are noted in the “Comments” column.

Status	ICD-O-3.2 Morphology Code	Term(s)	Reportable Y/N	Comments
RT	8140/3	Acinar adenocarcinoma of prostate (C61.9)	Y	
Syn	8744/3	Acral lentiginous melanoma, malignant (C44. _)	Y	
PT	8744/3	Acral melanoma (C44. _)	Y	
BC	8158/3	ACTH-producing tumor	Y	Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021
PT	9840/3	Acute erythroid leukemia	Y	
CC	9687/3	Acute leukemia, Burkitt type [obs]	Y	Cases diagnosed prior to 1/1/2021 use code 9826/3 Cases diagnosed 1/1/2021 forward use code 9687/3
CC	9687/3	Acute lymphoblastic leukemia, mature B-cell type	Y	Cases diagnosed prior to 1/1/2021 use code 9826/3 Cases diagnosed 1/1/2021 forward use code 9687/3
NC/T	9912/3	Acute myeloid leukemia with BCR-ABL1	Y	Reportable for cases diagnosed 1/1/2021 forward
NC/T	9878/3	Acute myeloid leukemia with biallelic mutations of CEBPA	Y	Reportable for cases diagnosed 1/1/2021 forward
NC/T	9877/3	Acute myeloid leukemia with mutated NPM1	Y	Reportable for cases diagnosed 1/1/2021 forward
NC/T	9879/3	Acute myeloid leukemia with mutated RUNX1	Y	Reportable for cases diagnosed 1/1/2021 forward
Syn	9840/3	Acute myeloid leukemia, M6 type	Y	
Syn	8140/3	Adenocarcinoma, usual type	Y	
PT	8390/3	Adnexal adenocarcinoma (C44. _)	Y	
Syn	8700/3	Adrenal medullary paraganglioma (C74.1)	Y	Reportable for cases diagnosed 1/1/2021 forward.

				Not reportable prior to 1/1/2021
Syn/BC	8408/3	Aggressive digital papillary adenoma (C44. _) see comments*	See comments	The term “ <i>Aggressive digital papillary adenoma</i> ” has changed behavior from /1 to /3. Cases diagnosed prior to 1/1/2021 with this term are not reportable. Cases with this term diagnosed 1/1/2021 and after are reportable
Syn	9310/3	Ameloblastoma, malignant	Y	
PT	9310/3	Ameloblastoma, metastasizing	Y	
NC/T	9715/3	Anaplastic large cell lymphoma, ALK negative	Y	Reportable for cases diagnosed 1/1/2021 forward
RT	8020/3	Anaplastic undifferentiated carcinoma (C73.9)	Y	
Syn	8691/3	Aortic body paraganglioma (C75.5)	Y	Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021
BC Syn Syn	8691/3	Aortic body tumor (C75.5)	Y	Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021
Syn	8691/3	Aorticopulmonary paraganglioma (C75.5)	Y	Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021
Syn	8249/3	Atypical carcinoid tumor	Y	
CC	9687/3	B-ALL [obs]	Y	Cases diagnosed prior to 1/1/2021 use code 9826/3 Cases diagnosed 1/1/2021 forward use code 9687/3
RT	8090/3	Basal cell carcinoma with adnexal differentiation (C44. _)	N	Not reportable

Syn	8833/1	Bednar tumor (C44. _)	N	Cases diagnosed prior to 1/1/2021, report the case and code to 8833/3. Cases diagnosed 1/1/2021 forward are not reportable.
Syn	8151/3	Beta cell adenoma (C25.4)	Y	Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021.
Syn	8151/3	Beta cell tumor, malignant (C25.4)	Y	Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021.
NC/T	9819/3	B-lymphocytic leukemia/lymphoma, BCR-ABL1-like	Y	Reportable for cases diagnosed 1/1/2021 forward
RT	9715/3	Breast implant-associated anaplastic large cell lymphoma (C50. _)	Y	Reportable for cases diagnosed 1/1/2021 forward
Syn	9699/3	Bronchus associated lymphoid tissue lymphoma	Y	
CC	9687/3	Burkitt cell leukemia (see also M-9687/3)	Y	Cases diagnosed prior to 1/1/2021 use code 9826/3 Cases diagnosed 1/1/2021 forward use code 9687/3
CC	9811/3	c-ALL	Y	Cases diagnosed prior to 1/1/2021 use code 9836/3 Cases diagnosed 1/1/2021 forward use code 9811/3
RT	8140/3	Carcinoma of Skene, Cowper and Littre Glands	Y	
Syn	8589/3	Carcinoma showing thymus-like element	Y	
RT	8020/3	Carcinoma, poorly differentiated, NOS	Y	
BC	8692/3	Carotid body paraganglioma (C75.4)	Y	Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021

Syn	8692/3	Carotid body tumor (C75.4)	Y	Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021
RT	8693/3	Chemodectoma	Y	Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021
Syn	8700/3	Chromaffin paraganglioma	Y	Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021
Syn	8700/3	Chromaffin tumor	Y	Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021
Syn	8700/3	Chromaffinoma	Y	Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021
RT	8313/1	Clear cell adenofibroma of borderline malignancy (C56.9)	N	Not reportable
PT	8313/1	Clear cell borderline tumor (C56.9)	N	Not reportable
Syn	8313/1	Clear cell cystic tumor of borderline malignancy (C56.9)	N	Not reportable
Syn	8313/1	Clear cell tumor, atypical proliferation (C56.9)	N	Not reportable
PT	9473/3	CNS Embryonal tumor, NOS	Y	
CC	9811/3	Common ALL	Y	Cases diagnosed prior to 1/1/2021 use code 9836/3 Cases diagnosed 1/1/2021 forward use code 9811/3
CC	9811/3	Common precursor B ALL	Y	Cases diagnosed prior to 1/1/2021 use code 9836/3 Cases diagnosed 1/1/2021 forward use code 9811/3

RT	8693/3	Composite paraganglioma	Y	Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021
RT	8700/3	Composite pheochromocytoma (C74.1)	Y	Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021
RT/BC	8500/2	Cystic hypersecretory carcinoma (C50. _)	Y	Cases diagnosed prior to 1/1/2021, code to 8508/3. ICD-O-3.2 now lists this term under 8500 with a behavior code of 2.
RT	8020/3	Dedifferentiated carcinoma	Y	
BC	8832/1	Dermatofibrosarcoma protuberans, NOS	N	Cases diagnosed prior to 1/1/2021, report the case and code to 8832/3. Cases diagnosed 1/1/2021 forward are not reportable.
Syn	8832/1	Dermatofibrosarcoma, NOS	N	Cases diagnosed prior to 1/1/2021, report the case and code to 8832/3. Cases diagnosed 1/1/2021 forward are not reportable.
Syn	8832/3	Dermatofibrosarcoma, sarcomatous (C44. _)	Y	
RT	9680/3	Diffuse large B-cell lymphoma, activated B-cell subtype	Y	
RT	9680/3	Diffuse large B-cell lymphoma, germinal center B-cell subtype	Y	
PT	9680/3	Diffuse large B-cell lymphoma, NOS	Y	
PT	8408/3	Digital papillary adenocarcinoma (C44. _)	Y	
RT	8720/3	Early/Evolving invasive melanoma (C44. _)	Y	"Early/evolving invasive melanoma" is reportable for

				cases diagnosed 1/1/2021 forward
RT	8720/2	Early/Evolving melanoma in situ (C44. _)	Y	Early/Evolving melanoma in situ is reportable for cases diagnosed 1/1/2021 forward
Syn	8408/3	Eccrine papillary adenocarcinoma (C44. _)	Y	
Syn	8409/3	Eccrine poroma, malignant (C44. _)	Y	
PT	8921/3	Ectomesenchymoma	Y	
Syn	8273/3	Embryoma	Y	Reportable for cases diagnosed 1/1/2021 forward
RT	8509/3	Endocrine mucin-producing sweat gland carcinoma (C44. _)	Y	
RT	8509/2	Endocrine mucin-producing sweat gland carcinoma in situ (C44. _)	Y	
RT	8158/3	Endocrine tumor, functioning, NOS	Y	Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021
RT	8140/3	Endolymphatic sac tumor	Y	
BC	8380/2	Endometrioid intraepithelial neoplasia (C54.1)	Y	Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021
NC/T	9749/3	Erdheim-Chester Disease	Y	Reportable for cases diagnosed 1/1/2021 forward
PT	9364/3	Ewing sarcoma	Y	1/1/2021 forward Ewing sarcoma is the preferred term for 9364/3 and is no longer coded to 9260/3. Cases diagnosed prior to 1/1/2021 should be coded to 9260/3.
BC	8693/3	Extra-adrenal paraganglioma, NOS	Y	Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021

CC	9687/3	FAB L3 [obs]	Y	Cases diagnosed prior to 1/1/2021 use code 9826/3 Cases diagnosed 1/1/2021 forward use code 9687/3
Syn	8330/3	Follicular adenocarcinoma (C73.9)	Y	
BC	8335/1	Follicular carcinoma, encapsulated	N	Cases diagnosed prior to 1/1/2021 are reportable and coded to 8335/3. Cases diagnosed 1/1/2021 and after are not reportable.
PT	8330/3	Follicular carcinoma, NOS (C73.9)	Y	
RT	9695/3	Follicular lymphoma, duodenal type (C17.0)	Y	
RT	9690/3	Follicular lymphoma, pediatric type	Y	
PT	8335/1	Follicular tumor of uncertain malignant potential	N	
Syn	8936/3	GANT	Y	Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021
RT	8936/3	Gastrointestinal autonomic nerve tumor	Y	Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021
RT	8936/3	Gastrointestinal pacemaker cell tumor	Y	Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021
Syn	8936/3	Gastrointestinal stromal sarcoma	Y	Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021
BC	8936/3	Gastrointestinal stromal tumor	Y	Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021

Syn	9411/3	Gemistocytic astrocytoma IDH mutant (C71. _)	Y	
Syn	8936/3	GIST, malignant	Y	Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021
Syn	8690/3	Glomus jugulare tumor, NOS (C75.5)	Y	Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021
Syn	8315/3	Glycogen-rich clear cell carcinoma	Y	
BC	8620/3	Granulosa cell tumor, adult type (C56.9)	Y	Granulosa cell tumor, adult type of the ovary diagnosed prior to 1/1/2021 are not reportable. Cases diagnosed 1/1/2021 forward are now reportable.
Syn	8815/3	Hemangiopericytoma, malignant	Y	Cases diagnosed prior to 1/1/2021 use code 9150/3 Cases diagnosed 1/1/2021 forward use code 8815/3
PT	9738/3	HHV8-positive diffuse B-cell lymphoma	Y	
PT	8402/3	Hidradenocarcinoma (C44. _)	Y	
Syn	8077/2	High grade squamous intraepithelial lesion	Y	
BC	9725/1	Hydroa vacciniforme-like lymphoproliferative disorder	N	Cases diagnosed prior to 1/1/2021, report the case and code to 9725/3. Cases diagnosed 1/1/2021 forward are not reportable
BC	9080/1	Immature teratoma of the lung (C34. _)	N	Immature teratomas arising in lung are not reportable for cases diagnosed 1/1/2021 forward.

BC	9080/1	Immature teratoma of the thymus (C37.9)	N	Immature teratomas arising in thymus are not reportable for cases diagnosed 1/1/2021 forward.
BC	9080/1	Immature teratoma of the thyroid (C73.9)	N	Immature teratomas arising in thyroid are not reportable for cases diagnosed 1/1/2021 forward.
Syn	9685/1	In situ follicular lymphoma	N	In situ lymphoma is not reportable
NC	9695/1	In situ follicular neoplasm	N	In situ lymphoma is not reportable
Syn	9673/1	In situ mantle cell lymphoma	N	Not reportable
NC/T	9673/1	In situ mantle cell neoplasm	N	Not reportable
Syn	8337/3	Insular carcinoma (C73.9)	Y	
BC	8151/3	Insulinoma, NOS (C25.4)	Y	Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021.
RT	8580/3	Intrapulmonary thymoma (C37.9)	Y	"Malignant" removed from pre-ICD-O-3.2 term
PT	8589/3	Intrathyroid thymic carcinoma (C73.9)	Y	
RT	8150/3	Islet cell adenocarcinoma (C25.4)	Y	Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021
RT	8150/3	Islet cell adenoma (C25.4)	Y	Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021
RT	8150/3	Islet cell adenomatosis (C25.4)	Y	Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021

RT	8150/3	Islet cell carcinoma (C25.4)	Y	Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021
RT	8150/3	Islet cell tumor, NOS (C25.4)	Y	Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021
Syn	8690/3	Jugular paraganglioma (C75.5)	Y	Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021
Syn	8690/3	Jugulotympanic paraganglioma (C75.5)	Y	Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021
RT	8071/3	Keratoacanthoma	Y	
BC	9751/1	Langerhans cell histiocytosis, NOS Langerhans cell histiocytosis, monostotic Langerhans cell histiocytosis, polystotic	N N N	Please note, these terms are not reportable. Refer to Hematopoietic Database for reportable terms. Cases diagnosed prior to 1/1/2021, report the case and code to 9751/3. Cases diagnosed 1/1/2021 forward are not reportable
Syn	9738/3	Large B-cell lymphoma arising in HHV8-associated multicentric Castleman disease	Y	
RT	9698/3	Large B-cell lymphoma with IRF4 rearrangement	Y	
RT	8693/3	Laryngeal paraganglioma	Y	Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021
PT	8743/3	Low cumulative sun damaged melanoma (C44. _)	Y	

BC	9718/1	Lymphoid papulosis (C44. _)	N	Cases diagnosed prior to 1/1/2021, report the case and code to 9718/3. Cases diagnosed 1/1/2021 forward are not reportable
BC	9766/3	Lymphomatoid granulomatosis, grade 3	Y	Reportable for cases diagnosed 1/1/2021 forward
Syn	9680/3	Malignant lymphoma, large B-cell, diffuse, NOS	Y	
CC	9823/3	Malignant lymphoma, lymphocytic, diffuse, NOS	Y	Cases diagnosed prior to 1/1/2021 use code 9670/3 Cases diagnosed 1/1/2021 forward use code 9823/3
CC	9823/3	Malignant lymphoma, lymphocytic, NOS	Y	Cases diagnosed prior to 1/1/2021 use code 9670/3 Cases diagnosed 1/1/2021 forward use code 9823/3
CC	9823/3	Malignant lymphoma, lymphocytic, well differentiated, diffuse	Y	Cases diagnosed prior to 1/1/2021 use code 9670/3 Cases diagnosed 1/1/2021 forward use code 9823/3
CC	9823/3	Malignant lymphoma, small B lymphocytic, NOS (see also M-9823/3)	Y	Cases diagnosed prior to 1/1/2021 use code 9670/3 Cases diagnosed 1/1/2021 forward use code 9823/3
CC	9823/3	Malignant lymphoma, small cell diffuse	Y	Cases diagnosed prior to 1/1/2021 use code 9670/3 Cases diagnosed 1/1/2021 forward use code 9823/3
CC	9823/3	Malignant lymphoma, small cell, NOS	Y	Cases diagnosed prior to 1/1/2021 use code 9670/3 Cases diagnosed 1/1/2021 forward use code 9823/3
CC	9823/3	Malignant lymphoma, small lymphocytic, diffuse	Y	Cases diagnosed prior to 1/1/2021 use code 9670/3

				Cases diagnosed 1/1/2021 forward use code 9823/3
CC	9823/3	Malignant lymphoma, small lymphocytic, NOS	Y	Cases diagnosed prior to 1/1/2021 use code 9670/3 Cases diagnosed 1/1/2021 forward use code 9823/3
PT	8761/3	Malignant melanoma arising in giant congenital nevus (C44. _)	Y	
Syn	8761/3	Malignant melanoma in giant pigmented nevus (C44. _)	Y	
Syn	8982/3	Malignant myoepithelioma	Y	
Syn	8963/3	Malignant rhabdoid tumor	Y	
PT	8770/3	Malignant Spitz tumor (C44. _)	Y	
RT	8510/3	Medullary-like carcinoma	Y	
RT	9477/3	Medulloblastoma, group 3 (C71.6)	Y	
RT	9477/3	Medulloblastoma, group 4 (C71.6)	Y	
RT	9475/3	Medulloblastoma, WNT-activated, anaplastic type (C71.6)	Y	
RT	9475/3	Medulloblastoma, WNT-activated, classic (C71.6)	Y	
RT	9475/3	Medulloblastoma, WNT-activated, large cell type (C71.6)	Y	
Syn	8780/3	Melanoma arising in a blue nevus (C44. _)	Y	
RT	8720/3	Melanoma, meningeal (C70. _)	Y	
RT	8580/3	Metaplastic thymoma (C37.9)	Y	"Malignant" removed from pre-ICD-O-3.2 term
PT	8407/3	Microcystic adnexal carcinoma (C44. _)	Y	
BC	8690/3	Middle ear paraganglioma (C75.5)	Y	Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021
Syn	8244/3	Mixed carcinoid and adenocarcinoma	Y	
RT	8770/3	Mixed epithelioid and spindle cell melanoma	Y	
Syn	8482/3	Mucinous adenocarcinoma, endocervical type	Y	
RT	8470/2	Mucinous cystadenocarcinoma, non-invasive (C25. _)	Y	
BC	8470/2	Mucinous cystic neoplasm with high grade dysplasia (C25. _)	Y	

Syn	9699/3	Mucosa associated lymphoid tissue lymphoma	Y	
Syn	8091/3	Multifocal superficial basal cell carcinoma (C44. _)	N	Not reportable
BC	9505/0	Multinodular and vasculating neuronal tumor (MVNT) (C71.2)	Y	WHO has not yet assigned a specific ICD-O code for this neoplasm. In the interest of collecting these tumors, 9505/0 has been assigned by neuropathology experts.
Syn	9732/3	Multiple myeloma (C42.1)	Y	
Syn	9986/3	Myelodysplastic syndrome with 5q deletion (5q-) syndrome	Y	
PT	9986/3	Myelodysplastic syndrome with isolated del (5q)	Y	
PT	9985/3	Myelodysplastic syndrome with multilineage dysplasia	Y	
PT	9993/3	Myelodysplastic syndrome with ring sideroblasts and multilineage dysplasia	Y	
PT	9982/3	Myelodysplastic syndrome with ring sideroblasts and single lineage dysplasia	Y	
PT	9980/3	Myelodysplastic syndrome with single lineage dysplasia	Y	
NC/T	9968/3	Myeloid/lymphoid neoplasm with PCM1-JAK2	Y	Reportable for cases diagnosed 1/1/2021 forward
PT	8982/3	Myoepithelial carcinoma	Y	
RT	8150/3	Nesidioblastoma (C25.4)	Y	Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021
PT	8249/3	Neuroendocrine tumor, grade 2	Y Y Y	
RT	8249/3	Neuroendocrine tumor, grade 3	Y	
Removed from	9540/1	Neurofibromatosis, NOS	N	WHO has removed neurofibromatosis from ICD-O-3.2. This disease is not

ICD-O-3.2				reportable for cases diagnosed 1/1/2018 forward per Solid Tumor Rules
RT	8720/3	Nevoid melanoma (C44. _)	Y	
Syn	8402/3	Nodular hidradenoma, malignant (C44. _)	Y	
RT	8693/3	Nonchromaffin paraganglioma, NOS	Y	Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021
NC/T	8349/1	Non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) C73.9	N	This term was previously coded to 8343/2 and was reportable. This term has changed both ICD-O and behavior codes and is no longer reportable for cases diagnosed 1/1/2021 forward.
NC/T	8349/1	Non-invasive FTP	N	This term was previously coded to 8343/2 and was reportable. This term has changed both ICD-O and behavior codes and is no longer reportable for cases diagnosed 1/1/2021 forward
Syn	8150/3	Pancreatic endocrine tumor, nonfunctioning (C25.4)	Y	Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021
Syn	8150/3	Pancreatic endocrine tumor, NOS (C25.4)	Y	Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021
BC	8150/3	Pancreatic neuroendocrine tumor, nonfunctioning (C25.4)	Y	Reportable for cases diagnosed 1/1/2021 forward.

				Not reportable prior to 1/1/2021.
PT	8342/3	Papillary carcinoma, oncocytic variant (C73.9)	Y	
Syn	8342/3	Papillary carcinoma, oxyphilic cell (C73.9)	Y	
CC	8470/3	Papillary mucinous cystadenocarcinoma (C56.9)	Y	Cases diagnosed prior to 1/1/2021 use code 8471/3 Cases diagnosed 1/1/2021 forward use code 8470/3
CC	8470/3	Papillary pseudomucinous cystadenocarcinoma (C56.9)	Y	Cases diagnosed prior to 1/1/2021 use code 8471/3 Cases diagnosed 1/1/2021 forward use code 8470/3
Syn	8441/3	Papillary serous adenocarcinoma (C56.9)	Y	Cases diagnosed prior to 1/1/2021 use code 8460/3
Syn	8441/3	Papillary serous cystadenocarcinoma (56.9)	Y	Cases diagnosed prior to 1/1/2021 use code 8460/3
Syn	8130/1	Papillary transitional cell neoplasm of low-malignant potential (C67. _)	N	Not reportable
PT	8130/1	Papillary urothelial neoplasm of low-malignant potential (C67. _)	N	Not reportable
RT	8083/3	Papillary-basaloid carcinoma	Y	
BC	8680 1 /3	Paraganglioma, NOS (C75.5)	Y	Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021
BC	8682/3	Parasympathetic paraganglioma (C75.5)		Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021
RT	8140/3	Parathyroid tumor (C75.0)	Y	
Syn	8700/3	Pheochromoblastoma (C74.1)	Y	Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021

BC	8700/3	Pheochromocytoma, NOS (C74.1)	Y	Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021
BC Syn	8833/1	Pigmented dermatofibrosarcoma protuberans (C44. _)	N	Cases diagnosed prior to 1/1/2021, report the case and code to 8833/3. Cases diagnosed 1/1/2021 forward are not reportable.
PT Syn	8110/3	Pilomatrix carcinoma (C44. _) Pilomatrix carcinoma (C44. _)	N N	Not reportable Not reportable
NC/T	8273/3	Pituitary blastoma (C75.1)	Y	Reportable for cases diagnosed 1/1/2021 forward
PT	9732/3	Plasma cell myeloma (C42.1)	Y	
Syn	8802/3	Pleomorphic cell sarcoma, undifferentiated	Y	
RT	8802/3	Pleomorphic dermal sarcoma (C44. _)	Y	
Syn	8802/3	Pleomorphic sarcoma	Y	
BC	9971/3	Polymorphic post-transplant lymphoproliferative disorder	N	Cases diagnosed prior to 1/1/2021, report the case and code to 9971/3. Cases diagnosed 1/1/2021 forward are not reportable
Syn	8246/3	Poorly differentiated neuroendocrine neoplasm	Y	
PT	8337/3	Poorly differentiated thyroid carcinoma (C73.9)	Y	
PT	8409/3	Porocarcinoma (C44. _)	Y	
BC	9971/1	Post-transplant lymphoproliferative disorder, NOS	N	Cases diagnosed prior to 1/1/2021, report the case and code to 9971/3. Cases diagnosed 1/1/2021 forward are not reportable
CC	9811/3	Pre-B ALL	Y	Cases diagnosed prior to 1/1/2021 use code 9836/3

				Cases diagnosed 1/1/2021 forward use code 9811/3
CC	9811/3	Precursor B-cell lymphoblastic leukemia (see also M-9728/3)	Y	Cases diagnosed prior to 1/1/2021 use code 9836/3 Cases diagnosed 1/1/2021 forward use code 9811/3
CC	9811/3	Precursor B-cell lymphoblastic lymphoma (<i>see also M-9836/3</i>)	Y	Cases diagnosed prior to 1/1/2021 use code 9728/3 Cases diagnosed 1/1/2021 forward use code 9811/3
CC	9837/3	Precursor T-cell lymphoblastic lymphoma (see also M-9837/3)	Y	Cases diagnosed prior to 1/1/2021 use code 9729/3 Cases diagnosed 1/1/2021 forward use code 9837/3
CC	9811/3	Pre-pre-B ALL	Y	Cases diagnosed prior to 1/1/2021 use code 9836/3 Cases diagnosed 1/1/2021 forward use code 9811/3
RT	9699/3	Primary choroidal lymphoma (C69.3)	Y	
BC	9718/1	Primary cutaneous CD30+ T cell lymphoproliferative disorder (C44. _)	N	Cases diagnosed prior to 1/1/2021, report the case and code to 9718/3. Cases diagnosed 1/1/2021 forward are not reportable
BC	9709/1	Primary cutaneous CD4-positive small/medium T-cell lymphoma (C44. _)	N	Cases diagnosed prior to 1/1/2021, report the case and code to 9709/3. Cases diagnosed 1/1/2021 forward are not reportable
CC	9811/3	Pro-B ALL	Y	Cases diagnosed prior to 1/1/2021 use code 9836/3 Cases diagnosed 1/1/2021 forward use code 9811/3
RT	8074/3	Pseudovascular squamous cell carcinoma	Y	

BC	9971/3	PTLD, NOS	N	Cases diagnosed prior to 1/1/2021, report the case and code to 9971/3. Cases diagnosed 1/1/2021 forward are not reportable
Syn	9980/3	Refractory anemia		
Syn	9982/3	Refractory anemia with excess blasts, NOS	Y	
RT	9985/3	Refractory cytopenia of childhood	Y	
Syn	9985/3	Refractory cytopenia with multilineage dysplasia	Y	
CC	9980/3	Refractory neutropenia	Y	Cases diagnosed prior to 1/1/2021 use code 9991/3 Cases diagnosed 1/1/2021 forward use code 9980/3
CC	9980/3	Refractory thrombocytopenia	Y	Cases diagnosed prior to 1/1/2021 use code 9992/3 Cases diagnosed 1/1/2021 forward use code 9980/3
PT	8963/3	Rhabdoid tumor, NOS	Y	
Syn	8921/3	Rhabdomyosarcoma with ganglionic differentiation	Y	
Syn	8912/3	Rhabdomyosarcoma, spindle-cell/sclerosing type	Y	
Syn	8407/3	Sclerosing sweat duct carcinoma (C44. _)	Y	
RT	8580/3	Sclerosing thymoma (C37.9)	Y	"Malignant" removed from pre-ICD-O-3.2 term
Syn	8410/3	Sebaceous adenocarcinoma (C44. _)	Y	
PT	8410/3	Sebaceous carcinoma (C44. _)	Y	
PT	9391/3	Sellar ependymoma (C75.1)	Y	
PT	8441/3	Serous cystadenocarcinoma, NOS (56.9)	Y	Cases diagnosed prior to 1/1/2021 use code 8460/3
Syn	8441/3	Serous papillary adenocarcinoma, NOS (C56.9)	Y	Cases diagnosed prior to 1/1/2021 use code 8460/3
Syn	8441/3	Serous surface papillary carcinoma (C56.9)	Y	Cases diagnosed prior to 1/1/2021 use code 8460/3
Syn	8390/3	Skin appendage carcinoma (C44. _)	Y	
Syn	8230/3	Solid adenocarcinoma, NOS	Y	

RT	8452/3	Solid pseudopapillary carcinoma	Y	
PT	8452/3	Solid pseudopapillary neoplasm of the pancreas (C25. _)	Y	
RT	8120/3	Squamotransitional carcinoma	Y	
Syn	8077/2	Squamous dysplasia, high grade	Y	
Syn	8077/2	Squamous intraepithelial neoplasm, grade II	See comments	The term “squamous intraepithelial neoplasm, grade II” is NOT reportable for C53. _
PT	8091/3	Superficial basal cell carcinoma (C44. _)	N	Not reportable
RT	8743/3	Superficial spreading melanoma (C44. _)	Y	
RT	8200/3	Thymic carcinoma with adenoid cystic carcinoma-like features (C37.9)	Y	
RT	8585/3	Thymoma, atypical (C37.9)	Y	“Malignant” removed from pre-ICD-O-3.2 term
RT	8585/3	Thymoma, epithelial (C37.9)	Y	“Malignant” removed from pre-ICD-O-3.2 term
RT	8583/3	Thymoma, lymphocyte-rich (C37.9)	Y	“Malignant” removed from pre-ICD-O-3.2 term
RT	8583/3	Thymoma, lymphocytic (C37.9)	Y	“Malignant” removed from pre-ICD-O-3.2 term
RT	8581/3	Thymoma, medullary (C37.9)	Y	“Malignant” removed from pre-ICD-O-3.2 term
RT	8582/3	Thymoma, mixed type (C37.9)	Y	“Malignant” removed from pre-ICD-O-3.2 term
PT	8580/3	Thymoma, NOS (C37.9)	Y	“Malignant” removed from pre-ICD-O-3.2 term
RT	8583/3	Thymoma, organoid (C37.9)	Y	“Malignant” removed from pre-ICD-O-3.2 term
RT	8583/3	Thymoma, predominantly cortical (C37.9)	Y	“Malignant” removed from pre-ICD-O-3.2 term
RT	8581/3	Thymoma, spindle cell (C37.9)	Y	“Malignant” removed from pre-ICD-O-3.2 term

PT	8581/3	Thymoma, type A (C37.9)	Y	"Malignant" removed from pre-ICD-O-3.2 term
PT	8582/3	Thymoma, type AB (C37.9)	Y	"Malignant" removed from pre-ICD-O-3.2 term
PT	8583/3	Thymoma, type B1 (C37.9)	Y	"Malignant" removed from pre-ICD-O-3.2 term
PT RT	8584/3	Thymoma, type B2 (C37.9) Thymoma, cortical (C37.9)	Y Y	"Malignant" removed from pre-ICD-O-3.2 term
PT	8585/3	Thymoma, type B3 (C37.9)	Y	"Malignant" removed from pre-ICD-O-3.2 term
Syn	8131/3	Transitional cell carcinoma, micropapillary	Y	
Syn	8122/3	Transitional cell carcinoma, spindle cell		
PT	8122/3	Urothelial carcinoma, sarcomatoid	Y	
Syn	8122/3	Urothelial carcinoma, spindle cell	Y	
RT	8693/3	Vagal paraganglioma	Y	Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021
RT	9680/3	Vitreoretinal lymphoma (C69. _)	Y	
RT	8054/3	Warty-basaloid carcinoma	Y	